泛癌症分析鉴定出嗅觉受体家族 7 亚家族 A 成员 5 作为胶质瘤的一个潜在生物标志物。
Pan-cancer analysis identifies olfactory receptor family 7 subfamily A member 5 as a potential biomarker for glioma.
机构信息
Department of Medical Research Center, Shaoxing People's Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, Zhejiang, China.
Institute of Psychology, Chinese Academy of Sciences, Beijing, China.
出版信息
PeerJ. 2024 Jul 10;12:e17631. doi: 10.7717/peerj.17631. eCollection 2024.
BACKGROUND
Human olfactory receptors (ORs) account for approximately 60% of all human G protein-coupled receptors. The functions of ORs extend beyond olfactory perception and have garnered significant attention in tumor biology. However, a comprehensive pan-cancer analysis of ORs in human cancers is lacking.
METHODS
Using data from public databases, such as HPA, TCGA, GEO, GTEx, TIMER2, TISDB, UALCAN, GEPIA2, and GSCA, this study investigated the role of olfactory receptor family 7 subfamily A member 5 (OR7A5) in various cancers. Functional analysis of OR7A5 in LGG and GBM was performed using the CGGA database. Molecular and cellular experiments were performed to validate the expression and biological function of OR7A5 in gliomas.
RESULTS
The results revealed heightened OR7A5 expression in certain tumors, correlating with the expression levels of immune checkpoints and immune infiltration. In patients with gliomas, the expression levels of OR7A5 were closely associated with adverse prognosis, 1p/19p co-deletion status, and wild-type IDH status. Finally, experiments confirmed the inhibitory effect of OR7A5 knockdown on the proliferative capacity of glioma cells and on the expression levels of proteins related to lipid metabolism.
CONCLUSION
This study establishes OR7A5 as a novel biomarker, potentially offering a novel therapeutic target for gliomas.
背景
人类嗅觉受体(ORs)约占所有人类 G 蛋白偶联受体的 60%。ORs 的功能不仅限于嗅觉感知,在肿瘤生物学中受到了广泛关注。然而,目前缺乏对人类癌症中 ORs 的全面泛癌分析。
方法
本研究利用 HPA、TCGA、GEO、GTEx、TIMER2、TISDB、UALCAN、GEPIA2 和 GSCA 等公共数据库中的数据,研究了嗅觉受体家族 7 亚家族 A 成员 5(OR7A5)在各种癌症中的作用。使用 CGGA 数据库对 LGG 和 GBM 中的 OR7A5 进行功能分析。进行分子和细胞实验以验证 OR7A5 在神经胶质瘤中的表达和生物学功能。
结果
结果表明,某些肿瘤中 OR7A5 的表达水平升高,与免疫检查点和免疫浸润的表达水平相关。在胶质瘤患者中,OR7A5 的表达水平与不良预后、1p/19p 共缺失状态和野生型 IDH 状态密切相关。最后,实验证实了 OR7A5 敲低对神经胶质瘤细胞增殖能力和与脂质代谢相关蛋白表达水平的抑制作用。
结论
本研究确立了 OR7A5 作为一种新的生物标志物,为神经胶质瘤提供了一个新的潜在治疗靶点。